Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Favorable Outcome
100%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
100%
Pediatric Patients
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Blinatumomab
100%
Graft Failure
31%
Overall Survival
25%
Leukemia-free Survival
25%
Between-group
18%
Graft Rejection
18%
Graft-versus-host Disease (GvHD)
18%
Chemotherapy Alone
18%
Relapsed or Refractory
18%
Minimal Residual Disease
18%
Multivariable
12%
Remission
12%
Immune Toxicity
12%
Neutrophil Engraftment
12%
Non-relapse Mortality
12%
IV Immunoglobulin
12%
Platelet Engraftment
12%
Annualized Relapse Rate
12%
High Risk
6%
Pediatric
6%
Clinical Outcomes
6%
Immune Response
6%
Chemotherapy
6%
Transplantation
6%
B Cells
6%
Leukemic Blast
6%
Leukemic Cells
6%
Fisher's Exact Test
6%
Study Support
6%
Potential Risk
6%
Increased Incidence
6%
Lysis
6%
High Incidence
6%
Cytotoxic T Cells
6%
Reconstitution
6%
Kaplan-Meier Method
6%
Log-rank Test
6%
Cox Proportional Hazards Regression Model
6%
Cumulative Incidence
6%
Salvage Therapy
6%
Chi-square Test
6%
Bispecific T-cell Engager (BiTE)
6%
Single-center Retrospective Study
6%
Wilcoxon Rank Sum Test
6%
Categorical Variables
6%
Survival Estimation
6%
CD19
6%
Data Reporting
6%
Competing Risks
6%
Gray's Test
6%
HCT Outcomes
6%
Risk Method
6%
Delayed Engraftment
6%
Medicine and Dentistry
Cell Transplantation
100%
Pediatrics Patient
100%
Hematopoietic Cell
100%
Acute B-Cell Lymphoblastic Leukemia
100%
Blinatumomab
100%
Graft Failure
31%
Overall Survival
25%
Minimal Residual Disease
18%
Leukemia
18%
Graft Rejection
18%
Cumulative Incidence
18%
Immunoglobulin
12%
Neutrophil
12%
Platelet
12%
Graft Versus Host Reaction
12%
Pediatrics
6%
Prospective Study
6%
T Cell
6%
Infusion
6%
Proportional Hazards Model
6%
B Cell
6%
Retrospective Study
6%
Fisher Exact Test
6%
Cytotoxic T-Cell
6%
Kaplan Meier Method
6%
Log Rank Test
6%
Cohort Analysis
6%
Engraftment
6%
CD3 Antigen
6%
Chronic Graft Versus Host Disease
6%
Salvage Therapy
6%
Rank Sum Test
6%
Chi Square Test
6%
Survival Estimate
6%
Leukemia Survival
6%
Nursing and Health Professions
Cell Transplantation
100%
Acute Lymphoblastic Leukemia
100%
Pediatrics Patient
100%
Blinatumomab
100%
Graft Failure
31%
Overall Survival
25%
Leukemia
25%
Minimal Residual Disease
18%
Graft Rejection
18%
Immunoglobulin
12%
Graft Versus Host Reaction
12%
Remission
12%
Infusion
6%
Clinical Outcome
6%
Proportional Hazards Model
6%
Fisher Exact Test
6%
Kaplan Meier Method
6%
Cohort Analysis
6%
Salvage Therapy
6%
Rank Sum Test
6%
Log Rank Test
6%
Engraftment
6%
Chi Square Test
6%
CD3 Antigen
6%
Chronic Graft Versus Host Disease
6%
Efficacy
6%
Immunology and Microbiology
Hematopoietic Cell
100%
B Cell
100%
Cell Transplantation
100%
Blinatumomab
100%
Overall Survival
25%
Engraftment
18%
Neutrophil
12%
Intravenous Immunoglobulin
12%
Platelet
12%
Graft-Versus-Host Disease
12%
T Cell
6%
Cytotoxic T Cell
6%
CD3 Antigen
6%
Chronic Graft Versus Host Disease
6%
CD19
6%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Blinatumomab
100%
Graft Failure
31%
Chemotherapy
25%
Overall Survival
25%
Leukemia
25%
Minimal Residual Disease
18%
Graft Rejection
18%
Immunoglobulin
12%
Remission
12%
Graft Versus Host Reaction
12%
Prospective Study
6%
Retrospective Study
6%
Cohort Study
6%
CD3 Antigen
6%
Chronic Graft Versus Host Disease
6%